Cargando…

PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer

BACKGROUND: The outcomes of immune checkpoint inhibitors in cancer patients with liver metastases are poor, which may be related to a different tumor microenvironment in liver metastases from primary tumors. This study was aimed to analyze PD-L1 expression and the immune microenvironment status in l...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiao-Li, Luo, Xuan, Sheng, Hui, Wang, Yun, Chen, Dong-Liang, Li, Jia-Ning, Wang, Feng-Hua, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730753/
https://www.ncbi.nlm.nih.gov/pubmed/33308232
http://dx.doi.org/10.1186/s12967-020-02636-x
_version_ 1783621756484845568
author Wei, Xiao-Li
Luo, Xuan
Sheng, Hui
Wang, Yun
Chen, Dong-Liang
Li, Jia-Ning
Wang, Feng-Hua
Xu, Rui-Hua
author_facet Wei, Xiao-Li
Luo, Xuan
Sheng, Hui
Wang, Yun
Chen, Dong-Liang
Li, Jia-Ning
Wang, Feng-Hua
Xu, Rui-Hua
author_sort Wei, Xiao-Li
collection PubMed
description BACKGROUND: The outcomes of immune checkpoint inhibitors in cancer patients with liver metastases are poor, which may be related to a different tumor microenvironment in liver metastases from primary tumors. This study was aimed to analyze PD-L1 expression and the immune microenvironment status in liver metastases and compare the differences of PD-L1 expression between primary tumors and liver metastases of colorectal cancer. METHODS: 74 cases of pathologically confirmed colorectal cancer with liver metastasis underwent resection from our hospital were included. Tissue microarrays were used for the interpretation of PD-L1 expression, cluster of differentiation 4 (CD4) and CD8 density by immunohistochemistry. We evaluated the disparity between primary tumor and liver metastasis in PD-L1 expression, CD4 and CD8 density and analyzed the factors associated with obvious PD-L1 disparity. RESULTS: The expression of PD-L1 was positively related to the density of CD4 and CD8 in liver metastases. The expression of PD-L1 in liver metastases was higher than in primary tumors in certain subgroups, including patients with concurrent liver metastases (n = 63, p = 0.05), patients receiving concurrent resection of primary and metastatic tumors (n = 56, p = 0.04). The two subgroups generally reflected those without inconsistent external influences, such as treatment and temporal factors, between primary tumors and liver metastases. In these subgroups, the intrinsic differences of microenvironment between primary tumors and liver metastases could be identified. Furthermore, tumor differentiation [moderate vs. poor: OR = 0.23, 95% CI: 0.03–0.99, p = 0.05)] were demonstrated to be associated with obvious discordance of PD-L1 expression between primary tumors and liver metastases. CONCLUSIONS: The expression of PD-L1 in liver metastases was higher than in primary tumors in subgroups, reflecting intrinsic microenvironment differences between primary and metastatic tumors. Obvious discordance of PD-L1 expression between primary tumor and liver metastasis was significantly related to the tumor differentiation.
format Online
Article
Text
id pubmed-7730753
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77307532020-12-11 PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer Wei, Xiao-Li Luo, Xuan Sheng, Hui Wang, Yun Chen, Dong-Liang Li, Jia-Ning Wang, Feng-Hua Xu, Rui-Hua J Transl Med Research BACKGROUND: The outcomes of immune checkpoint inhibitors in cancer patients with liver metastases are poor, which may be related to a different tumor microenvironment in liver metastases from primary tumors. This study was aimed to analyze PD-L1 expression and the immune microenvironment status in liver metastases and compare the differences of PD-L1 expression between primary tumors and liver metastases of colorectal cancer. METHODS: 74 cases of pathologically confirmed colorectal cancer with liver metastasis underwent resection from our hospital were included. Tissue microarrays were used for the interpretation of PD-L1 expression, cluster of differentiation 4 (CD4) and CD8 density by immunohistochemistry. We evaluated the disparity between primary tumor and liver metastasis in PD-L1 expression, CD4 and CD8 density and analyzed the factors associated with obvious PD-L1 disparity. RESULTS: The expression of PD-L1 was positively related to the density of CD4 and CD8 in liver metastases. The expression of PD-L1 in liver metastases was higher than in primary tumors in certain subgroups, including patients with concurrent liver metastases (n = 63, p = 0.05), patients receiving concurrent resection of primary and metastatic tumors (n = 56, p = 0.04). The two subgroups generally reflected those without inconsistent external influences, such as treatment and temporal factors, between primary tumors and liver metastases. In these subgroups, the intrinsic differences of microenvironment between primary tumors and liver metastases could be identified. Furthermore, tumor differentiation [moderate vs. poor: OR = 0.23, 95% CI: 0.03–0.99, p = 0.05)] were demonstrated to be associated with obvious discordance of PD-L1 expression between primary tumors and liver metastases. CONCLUSIONS: The expression of PD-L1 in liver metastases was higher than in primary tumors in subgroups, reflecting intrinsic microenvironment differences between primary and metastatic tumors. Obvious discordance of PD-L1 expression between primary tumor and liver metastasis was significantly related to the tumor differentiation. BioMed Central 2020-12-11 /pmc/articles/PMC7730753/ /pubmed/33308232 http://dx.doi.org/10.1186/s12967-020-02636-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wei, Xiao-Li
Luo, Xuan
Sheng, Hui
Wang, Yun
Chen, Dong-Liang
Li, Jia-Ning
Wang, Feng-Hua
Xu, Rui-Hua
PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
title PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
title_full PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
title_fullStr PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
title_full_unstemmed PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
title_short PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
title_sort pd-l1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730753/
https://www.ncbi.nlm.nih.gov/pubmed/33308232
http://dx.doi.org/10.1186/s12967-020-02636-x
work_keys_str_mv AT weixiaoli pdl1expressioninlivermetastasisitsclinicalsignificanceanddiscordancewithprimarytumorincolorectalcancer
AT luoxuan pdl1expressioninlivermetastasisitsclinicalsignificanceanddiscordancewithprimarytumorincolorectalcancer
AT shenghui pdl1expressioninlivermetastasisitsclinicalsignificanceanddiscordancewithprimarytumorincolorectalcancer
AT wangyun pdl1expressioninlivermetastasisitsclinicalsignificanceanddiscordancewithprimarytumorincolorectalcancer
AT chendongliang pdl1expressioninlivermetastasisitsclinicalsignificanceanddiscordancewithprimarytumorincolorectalcancer
AT lijianing pdl1expressioninlivermetastasisitsclinicalsignificanceanddiscordancewithprimarytumorincolorectalcancer
AT wangfenghua pdl1expressioninlivermetastasisitsclinicalsignificanceanddiscordancewithprimarytumorincolorectalcancer
AT xuruihua pdl1expressioninlivermetastasisitsclinicalsignificanceanddiscordancewithprimarytumorincolorectalcancer